
Relife Drugs Private Limited
About Relife Drugs Private Limited
Data last updated:
Relife Drugs Private Limited is a private limited company based in Lucknow, Uttar Pradesh, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 30 May 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U51397UP2005PTC030071. Its GSTIN is 09AADCR0119B1ZY (Uttar Pradesh).
The company has an authorised share capital of ₹2 Lakh and a paid-up capital of ₹1.5 Lakh. It is led by directors including Madhuri Sharma and Asif Ikbal Khan.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at S – 301 Phase – 1st Transport Nagar, Lucknow, Uttar Pradesh, India – 226012.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.55 Cr, a growth of 21% compared to the previous year. For the same year it recorded a net profit of ₹1.81 Lakh (net margin 1.2%) and EBITDA of ₹2.44 Lakh (EBITDA margin 1.6%). Revenue has grown at a compounded annual rate (CAGR) of 12% over three years and 5% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Relife Drugs Private Limited's registered office is in Lucknow, Uttar Pradesh. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressS – 301 Phase – 1st Transport Nagar, Lucknow, Uttar Pradesh, India – 226012
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Relife Drugs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Relife Drugs is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Relife Drugs Private Limited, buy the company report.
Financials of Relife Drugs Private Limited
FY 2025 filings availableRelife Drugs Private Limited reported revenue of ₹1.55 Cr (up 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 5% over five years, including 21% growth in the latest year. EBITDA rose 26% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.44 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.81 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1.6% | ||||
| Net Profit Margin | 1.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Relife Drugs Private Limited, buy the company report.
Board of directors of Relife Drugs Private Limited
Relife Drugs has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Madhuri Sharma | Director | 30 May 2005 | 21 Years 5 Months | Current |
| Asif Ikbal Khan | Director | 30 May 2005 | 21 Years 5 Months | Current |
| Ravi Praksh Sharma Also directs: Almeda Lifesciences Private Limited | Director | 30 May 2005 | 21 Years 5 Months | Current |
Peer comparison
Relife Drugs Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Amstel Pharma Private Limited | ₹1.56 Cr (FY 2024) | 20.0% | Thrissur, Kerala, India | |||
| Asteroids Healthcare Private Limited | ₹1.56 Cr (FY 2024) | 5.0% | Jaipur, Rajasthan, India | |||
| Relife Drugs Private Limitedthis company | ₹1.55 Cr (FY 2025) | ₹1.81 Lakh | 1.2% | 21.0% | Lucknow, Uttar Pradesh, India | |
| Maximon Pharma Private Limited | ₹1.55 Cr (FY 2025) | 30.0% | New Delhi, Delhi, India | |||
| Inowell Pharma Private Limited | ₹1.55 Cr (FY 2025) | 33.0% | Indore, Madhya Pradesh, India |
To see the full peer comparison of Relife Drugs Private Limited, buy the company report.
Auditor
Relife Drugs Private Limited is audited by ARUN K RASTOGI & CO for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| ARUN K RASTOGI & CO | FY 2017 | 004265C |
Shareholding
The shareholding of Relife Drugs Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Relife Drugs Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Relife Drugs Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Relife Drugs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Relife Drugs has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AADCR0119B1ZY | Uttar Pradesh | Active | 23 Mar 2021 |
To see the full GST registrations and return filing status of Relife Drugs Private Limited, buy the company report.
Recent activity
Relife Drugs Private Limited has 3 board changes on record since 2005: 3 appointments. The latest: Asif Ikbal Khan was appointed as Director on 30 May 2005.
Frequently asked questions
Relife Drugs is an active private limited company based in Lucknow, Uttar Pradesh, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 30 May 2005 (21+ years old) and is registered under CIN U51397UP2005PTC030071.
Relife Drugs has 3 current directors:
- Madhuri Sharma - Director
- Asif Ikbal Khan - Director
- Ravi Praksh Sharma - Director
The latest financial statements of Relife Drugs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Relife Drugs is 09AADCR0119B1ZY, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Relife Drugs is U51397UP2005PTC030071. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Relife Drugs was incorporated on 30 May 2005, making it 21+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Relife Drugs by revenue are Amstel Pharma Private Limited, Asteroids Healthcare Private Limited, Maximon Pharma Private Limited, Inowell Pharma Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Asif Ikbal Khan was appointed as Director on 30 May 2005. Madhuri Sharma was appointed as Director on 30 May 2005. Ravi Praksh Sharma was appointed as Director on 30 May 2005.
The registered office of Relife Drugs is at S – 301 Phase – 1st Transport Nagar, Lucknow, Uttar Pradesh, India – 226012.
Relife Drugs operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
The compliance status of Relife Drugs is compliant as of 19 September 2026. The company is actively filing with the Registrar of Companies.

